Raymond Woosley - ARCA Biopharma Director
| ABIO Stock | USD 3.45 0.05 1.47% |
Director
Dr. Raymond L. Woosley, M.D., Ph.D. was appointed as Director of ARCA biopharma, Inc., effective July 26, 2013. Dr. Woosley is currently the President, Emeritus, of the Critical Path Institute, a nonprofit, publicprivate partnership with the United States Food and Drug Administration, of which he was a founder, and where he served as President, Chief Executive Officer and Chairman of the Board from 2005 to 2011. Since 2012, Dr. Woosley is also the President and Chairman of the Board of the Arizona Center for Education and Research on Therapeutics, an independent, nonprofit research and education organization dedicated to the safe use of medicines. Since 2001, Dr. Woosley has also been a Professor of Medicine and Pharmacology at The University of Arizona Health Sciences Center, and Professor, Emeritus, since 2012, where he was also Vice President for Health Sciences from 2001 to 2005, and Dean of the College of Medicine from 2001 to 2002. From 1988 to 2000, Dr. Woosley was a professor of pharmacology and medicine at the Georgetown University School of Medicine, where he was also Director of the Institute of Cardiovascular Sciences from 1994 to 2000, and Division Chief, Clinical Pharmacology, in the Department of Medicine from 1988 to 1994 since 2013.
| Age | 71 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Address | 10170 Church Ranch Way, Westminster, CO, United States, 80021 |
| Phone | 720 940 2200 |
| Web | https://www.arcabio.com |
Raymond Woosley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Raymond Woosley against ARCA Biopharma stock is an integral part of due diligence when investing in ARCA Biopharma. Raymond Woosley insider activity provides valuable insight into whether ARCA Biopharma is net buyers or sellers over its current business cycle. Note, ARCA Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell ARCA Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Raymond Woosley over two months ago Acquisition by Raymond Woosley of 6000 shares of ARCA Biopharma subject to Rule 16b-3 | ||
Raymond Woosley over three months ago Acquisition by Raymond Woosley of 8000 shares of ARCA Biopharma subject to Rule 16b-3 | ||
Raymond Woosley over six months ago Acquisition by Raymond Woosley of 3463 shares of ARCA Biopharma subject to Rule 16b-3 |
ARCA Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1102) % which means that it has lost $0.1102 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1357) %, meaning that it created substantial loss on money invested by shareholders. ARCA Biopharma's management efficiency ratios could be used to measure how well ARCA Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Tangible Assets is likely to drop to -0.15. In addition to that, Return On Capital Employed is likely to drop to -0.21. At this time, ARCA Biopharma's Intangibles To Total Assets are very stable compared to the past year. As of the 23rd of April 2024, Asset Turnover is likely to grow to 0.30, while Total Assets are likely to drop about 34.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Stephen Worland | TRACON Pharmaceuticals | 59 | |
| Paul Walker | TRACON Pharmaceuticals | 43 | |
| Patrick Vink | Spero Therapeutics | 54 | |
| William LaRue | TRACON Pharmaceuticals | 66 | |
| Antonio Neri | AN2 Therapeutics | 49 | |
| Lewis Hay | AN2 Therapeutics | 60 | |
| Martin Mattingly | TRACON Pharmaceuticals | 60 | |
| Elaine Jones | CytomX Therapeutics | 60 | |
| Gaurav Swarup | Instil Bio | 60 | |
| Frederick Gluck | CytomX Therapeutics | 82 | |
| John Pottage | Spero Therapeutics | N/A | |
| Gaggar | Instil Bio | 85 | |
| Wayne Kauth | Instil Bio | 79 | |
| Alfred Scheidegger | TRACON Pharmaceuticals | 58 | |
| William Lupien | Instil Bio | 73 | |
| JeanFranois Formela | Spero Therapeutics | 61 | |
| Ramana Rao | Instil Bio | N/A | |
| Michael Maslowski | Instil Bio | N/A | |
| George Rohlinger | Instil Bio | N/A | |
| YoungJin Kim | Rezolute | N/A | |
| Ted Wang | TRACON Pharmaceuticals | 50 | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.11 |
ARCA Biopharma Leadership Team
Elected by the shareholders, the ARCA Biopharma's board of directors comprises two types of representatives: ARCA Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ARCA. The board's role is to monitor ARCA Biopharma's management team and ensure that shareholders' interests are well served. ARCA Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ARCA Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Ozeroff, Sr. VP, General Counsel and Secretary | ||
| Raymond Woosley, Director | ||
| Brian Selby, Chief Accounting Officer and VP of Fin. | ||
| Thomas Keuer, Chief Officer | ||
| Jeffrey CPA, Chief Officer | ||
| Daniel Mitchell, Director | ||
| Robert Conway, Chairman of the Board | ||
| Linda Grais, Lead Independent Director | ||
| Anders Hove, Director | ||
| Michael Bristow, President CEO, Director |
ARCA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ARCA Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | 12.15 M | ||||
| Shares Outstanding | 14.5 M | ||||
| Shares Owned By Insiders | 1.20 % | ||||
| Shares Owned By Institutions | 71.80 % | ||||
| Number Of Shares Shorted | 195.73 K | ||||
| Price To Earning | (0.63) X | ||||
| Price To Book | 1.27 X | ||||
| EBITDA | (7.3 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ARCA Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ARCA Biopharma's short interest history, or implied volatility extrapolated from ARCA Biopharma options trading.
Pair Trading with ARCA Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with ARCA Stock
| 0.71 | ELYM | Eliem Therapeutics | PairCorr |
Moving against ARCA Stock
| 0.87 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.78 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
| 0.74 | ALKS | Alkermes Plc Financial Report 24th of April 2024 | PairCorr |
| 0.72 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
| 0.7 | PFE | Pfizer Inc Aggressive Push | PairCorr |
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Return On Assets (0.11) | Return On Equity (0.14) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.